$50 GLP-1 Drugs for Medicare: What to Know

What Trump Actually Said About GLP-1 Drug Pricing

President Trump announced that GLP-1 weight-loss medications would soon be available to Medicare patients for as little as $50 per month. The statement, made in May 2025, signals a potential shift in how the federal government approaches coverage for drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro).

This matters because GLP-1 drugs currently carry a list price of $900 to $1,400 per month without insurance. For the roughly 67 million Americans enrolled in Medicare, that cost has been largely out of reach for weight management purposes specifically.

The announcement is bold. But the details on how it gets implemented, and when, are still taking shape.

Why Medicare Coverage for GLP-1s Has Been Complicated

Medicare has covered GLP-1 drugs like semaglutide when prescribed for type 2 diabetes under Part D for years. The gap has been in coverage for obesity treatment as a standalone diagnosis.

A 2003 federal law, the Medicare Modernization Act, explicitly excluded drugs used "for weight loss" from Part D coverage. That restriction has blocked millions of Medicare enrollees from accessing these medications even when their doctors recommend them.

The Treat and Reduce Obesity Act, a bipartisan bill circulating in Congress for years, has aimed to close this gap. But it has not passed. The Trump announcement suggests the administration may move through executive or regulatory channels rather than waiting on legislation.

What Has Changed Recently

In early 2025, the Biden administration finalized a rule that would have allowed Medicare and Medicaid to cover anti-obesity medications, including GLP-1s. That rule was set to take effect but has faced uncertainty under the new administration. Trump's $50 announcement suggests a different but potentially broader approach to solving the same access problem.

Who Would Qualify Under This Proposal

The details are still emerging, but here is what is likely based on how Medicare drug coverage works:

• Medicare Part D enrollees with a documented diagnosis of obesity, defined as a BMI of 30 or higher, or overweight with a BMI of 27 or higher alongside at least one weight-related comorbidity such as type 2 diabetes, hypertension, cardiovascular disease, or sleep apnea.
• Beneficiaries whose prescribing physician has documented that GLP-1 therapy is medically appropriate for their clinical situation, since prior authorization requirements are expected to apply even under an expanded coverage framework.
• Medicare Advantage enrollees whose specific plan adopts the expanded GLP-1 coverage on its formulary, since Medicare Advantage plans set their own drug lists within federal guidelines and adoption timelines will vary by insurer and region.
• Patients already receiving GLP-1 therapy for type 2 diabetes under existing Part D coverage, who may see their cost-sharing structure change if the new pricing mechanism applies broadly to the semaglutide and tirzepatide drug class rather than only to weight-management-specific indications.
• Low-income Medicare beneficiaries enrolled in the Extra Help program, also known as the Low Income Subsidy, who may qualify for even lower cost-sharing than the proposed $50 threshold depending on how the benefit structure is finalized.

It is not yet clear whether the $50 figure refers to a monthly copay under a restructured Part D benefit, a federally negotiated price cap, or a manufacturer rebate program. Each of those mechanisms works differently and has different implications for how quickly the price change could reach patients.

What This Means for the 67 Million on Medicare

If the $50 price point is implemented as described, the impact would be substantial. Obesity affects roughly 40% of Medicare beneficiaries. Many of them have obesity-related conditions like heart disease, type 2 diabetes, hypertension, and joint problems that GLP-1 drugs have shown clinical benefit for.

Studies published in journals like the New England Journal of Medicine have demonstrated that semaglutide reduces the risk of major cardiovascular events in people with obesity and existing heart disease. That data already influenced the FDA's approval of Wegovy for cardiovascular risk reduction in 2024.

For older adults specifically, the benefits of GLP-1 medications extend beyond the scale. Reduced inflammation, improved blood sugar regulation, and lower cardiovascular risk all translate into fewer hospitalizations and potentially lower total Medicare spending over time. That makes the long-term economics more defensible than critics of the cost suggest.

What Medicare Patients Should Do Right Now

Do not wait for official policy to land before having a conversation with your doctor. If you are on Medicare and managing obesity alongside any related condition, ask your physician these questions:

1. Am I currently eligible for a GLP-1 prescription under my existing coverage or diagnosis?

2. Which Part D plan covers these medications at the lowest cost in my area?

3. Would tirzepatide or semaglutide be more appropriate for my health profile?

4. Are there manufacturer assistance programs I can use while federal coverage expands?

Some Medicare Advantage plans already offer partial GLP-1 coverage depending on the insurer and your state. It is worth checking your specific plan's formulary today.

What Patients Not on Medicare Should Know

If you are under 65, employed, or using private insurance, this federal announcement does not directly affect your costs yet. But it signals something important: GLP-1 pricing is under political pressure from multiple directions, and costs for all patients may eventually come down.

In the meantime, your best tools for lowering GLP-1 costs are:

• Manufacturer savings cards from Novo Nordisk and Eli Lilly, which can reduce monthly costs to as low as $25 for commercially insured patients who meet eligibility criteria, though these programs are not available to Medicare beneficiaries.
• Telehealth platforms that specialize in GLP-1 prescribing and often have negotiated pricing structures or bundled consultation and medication costs that come in significantly below retail pharmacy list prices.
• Compounded semaglutide or tirzepatide through a licensed 503A or 503B pharmacy, where legally available, which has offered meaningfully lower monthly costs for patients paying out of pocket, though regulatory access to compounded versions continues to evolve.
• GLP-1 coupon and discount programs through third-party platforms such as GoodRx or SingleCare, which can reduce cash-pay prices at certain pharmacies, particularly for patients without prescription drug coverage.
• 90-day supply fills rather than monthly fills, since many pharmacies and mail-order services offer lower per-dose pricing on larger supplies, and this approach also reduces the frequency of potential access disruptions.

The Bigger Picture: Why Drug Pricing for Obesity Matters

The United States spends over $170 billion per year on obesity-related medical costs, according to estimates from the CDC and academic researchers. GLP-1 medications, despite their high upfront cost, have the potential to reduce downstream spending on diabetes, cardiovascular procedures, joint replacements, and hospital admissions.

The political momentum behind GLP-1 access reflects this math. When both Republican and Democratic administrations take steps to expand coverage, it is usually because the economic case is becoming undeniable.

However, expanding coverage also raises valid questions about supply, pharmacy infrastructure, and whether the healthcare system has enough obesity-trained providers to support a surge in new patients. These are not reasons to delay access. They are reasons to build the system thoughtfully.

Concerns and Caveats Worth Knowing

A $50 announcement is not the same as a $50 prescription at your pharmacy tomorrow. Here is what could slow implementation:

• The announcement was made as a political statement and has not yet been formalized through rulemaking, legislation, or a specific CMS policy update, meaning the mechanism and timeline for reaching $50 per month at the pharmacy counter remain undefined.
• Implementation requires either a formal change to the 2003 Medicare Modernization Act's weight loss drug exclusion, a new CMS coverage determination, a negotiated manufacturer rebate agreement, or some combination of these, each of which involves its own timeline and regulatory process.
• Pharmaceutical manufacturers may challenge significant price controls or rebate requirements through legal or lobbying channels, which could delay or modify the final structure of any coverage expansion even after it is formally announced.
• Medicare Advantage plans, which cover roughly half of all Medicare enrollees, set their own formularies and cost-sharing structures within federal guidelines, meaning that even a federal coverage expansion would need to be adopted by individual plans, a process that typically unfolds during annual formulary update cycles.
• Supply chain and pharmacy infrastructure may not be immediately ready to absorb a large new wave of Medicare patients starting GLP-1 therapy, given that demand already strained supply during the semaglutide shortage of 2022 to 2024, and a coverage expansion of this scale could create similar pressure.

The direction of travel here is encouraging. But Medicare patients should not cancel their current cost-management strategies based on an announcement alone.